论文信息 - A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. - 字舞流文

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

M. Kaminski | K. Griffith | S. Jagannath | A. Jakubowiak | R. Vij | D. Vesole | D. Couriel | D. Lebovic | K. Stockerl-Goldstein | D. Dytfeld | Asra Ahmed | K. Detweiler-Short | A. Al-Zoubi | Tara B. Anderson | Terri L. Jobkar | Kathryn McDonnell | M. Mietzel | Brian K. Nordgren | Asra Z. Ahmed | Diane Durecki | Diane E Durecki | D. Durecki